伊布替尼联合维奈克拉一线治疗慢性淋巴细胞白血病中的免疫重建:2期CAPTIVATE研究
在CAPTIVATE研究(NCT02910583)微小残留病(MRD)队列中,评估一线接受3周期伊布替尼后13周期伊布替尼联合维奈克拉治疗的慢性淋巴细胞白血病(CLL)患者免疫细胞亚群。CLL细胞在维奈克拉启动后3周期内下降,T细胞、经典单核细胞和常规树突状细胞异常计数在6个月内恢复至健康供者水平,感染随时间总体减少。结果提示伊布替尼联合维奈克拉可恢复正常血液免疫组成。
要点
- 维奈克拉启动后3周期内CLL细胞下降,第16周期起确认uMRD患者CLL细胞水平与健康供者相似。
- T细胞、经典单核细胞和常规树突状细胞异常计数在6个月内恢复至健康供者水平。
- 感染随时间总体减少,与随机治疗无关,第16周期后12个月内安慰剂组数值最低。
核心结论
- 结果提供伊布替尼联合维奈克拉恢复正常血液免疫组成的有前景证据。
研究设计与样本
- CAPTIVATE研究(NCT02910583)MRD队列,患者一线接受3周期伊布替尼后13周期伊布替尼联合维奈克拉治疗。
- 确认uMRD患者随机分配至安慰剂组或伊布替尼组,未确认uMRD患者随机分配至伊布替尼组或伊布替尼联合维奈克拉组。
- 在7个时间点采集样本,与年龄匹配的健康供者比较免疫细胞亚群。
主要发现
- 维奈克拉启动后3周期内CLL细胞下降;第16周期起确认uMRD患者水平与健康供者相似(≤0.8 cells per μL),未确认uMRD患者略高于健康供者。
- 第16周期后4个月,随机分配至安慰剂组的患者正常B细胞恢复至健康供者水平。
- 无论随机治疗如何,T细胞、经典单核细胞和常规树突状细胞异常计数在6个月内恢复至健康供者水平,自基线中位变化分别为-49%、+101%和+91%;浆细胞样树突状细胞至第20周期恢复(+598%)。
- 感染随时间总体减少,与随机治疗无关,第16周期后12个月内安慰剂组数值最低。
- GLOW研究(NCT03462719)中固定疗程伊布替尼联合维奈克拉治疗患者样本证实CLL细胞持续消除和正常B细胞恢复。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). Patients with Confirmed undetectable MRD (uMRD) were randomly assigned to placebo or ibrutinib groups; patients without Confirmed uMRD were randomly assigned to ibrutinib or ibrutinib plus venetoclax groups. We compared immune cell subsets in samples collected at 7 time points with age-matched healthy donors. CLL cells decreased within 3 cycles after venetoclax initiation; from cycle 16 onward, levels were similar to healthy donor levels (HDL; ≤0.8 cells per μL) in patients with Confirmed uMRD and slightly above HDL in patients without Confirmed uMRD. By 4 months after cycle 16, normal B cells had recovered to HDL in patients randomly assigned to placebo. Regardless of randomized treatment, abnormal counts of T cells, classical monocytes, and conventional dendritic cells recovered to HDL within 6 months (median change from baseline -49%, +101%, and +91%, respectively); plasmacytoid dendritic cells recovered by cycle 20 (+598%). Infections generally decreased over time regardless of randomized treatment and were numerically lowest in patients randomly assigned to placebo within 12 months after cycle 16. Sustained elimination of CLL cells and recovery of normal B cells were confirmed in samples from patients treated with fixed-duration ibrutinib plus venetoclax in the GLOW study (NCT03462719). These results demonstrate promising evidence of restoration of normal blood immune composition with ibrutinib plus venetoclax.
引用
- Moreno C, Solman IG, Tam CS, et al. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv. 2023. PMID: 37315225. doi:10.1182/bloodadvances.2023010236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。